Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045933 | 0.86 | HDAC1 (0.59) | ALDH1A1SMN1; SMN2PKML3MBTL1 | |
| SCHEMBL17045918 | 0.85 | CYP2C19 (0.56) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL530979 | 0.84 | PDE4B (0.54) | ALDH1A1SMN1; SMN2PKMGAAPOLB | |
| SCHEMBL10039350 | 0.83 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL16334693 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL5410393 | 0.81 | GAA (0.61) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL9069764 | 0.80 | CYP2C19 (0.57) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL1237172 | 0.80 | F2RL1 (0.62) | ALDH1A1F2RL1POLB | |
| SCHEMBL530937 | 0.78 | IDO1 (0.47) | ALDH1A1SMN1; SMN2PKMGAAMAPT | |
| SCHEMBL13067926 | 0.78 | IDO1 (0.47) | ALDH1A1SMN1; SMN2PKMGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | ALDH1A1 351/4885SMN1; SMN2 3241/4885PKM 1775/4885 |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | MMP8, PLAU, KLKB1 | ALDH1A1 2405/4885SMN1; SMN2 4808/4885PKM 3192/4885 |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | ALDH1A1 351/4885SMN1; SMN2 3241/4885PKM 1775/4885 |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | HDAC1, HDAC2, HDAC4 | ALDH1A1 1054/4885SMN1; SMN2 4839/4885PKM 1745/4885 |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | ALDH1A1 351/4885SMN1; SMN2 3241/4885PKM 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.